{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T17:07:49Z","timestamp":1790356069604,"version":"4.1.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T00:00:00Z","timestamp":1785456000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T00:00:00Z","timestamp":1785456000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100013170","name":"Ono Pharmaceutical","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013170","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Oncol"],"published-print":{"date-parts":[[2026,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      The combination of encorafenib plus binimetinib (ENC\u2009+\u2009BIN) is approved for the treatment of\n                      <jats:italic>BRAF<\/jats:italic>\n                      V600-mutated thyroid cancer in Japan, based on a phase 2 trial. We update the efficacy and safety data for ENC\u2009+\u2009BIN of this phase 2 trial after prolonged follow-up.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      This multicenter, open-label, uncontrolled phase 2 trial evaluated the efficacy and safety of ENC\u2009+\u2009BIN in patients with unresectable locally advanced or metastatic\n                      <jats:italic>BRAF<\/jats:italic>\n                      V600-mutated thyroid cancer that was not amenable to curative treatment, who were refractory\/intolerant to\u2009\u2265\u20091 previous vascular endothelial growth factor receptor-targeted regimens, or were considered ineligible for these. The primary endpoint was the objective response rate (ORR). The secondary endpoints included progression-free survival (PFS) and overall survival (OS).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>We enrolled 22 patients: 17 with differentiated thyroid carcinoma (DTC) and 5 with anaplastic thyroid carcinoma (ATC). During a prolonged period with a median follow-up of 28.7\u00a0months (range: 3.4\u201340.6), 3 additional patients with DTC achieved partial responses, increasing the ORR to 68.2% (15\/22 patients with either DTC or ATC). Medians for PFS and OS were not reached for DTC and 17.7 and 24.3\u00a0months, respectively, for ATC. Common adverse events were eye disorder (5\/12), infections and infestations (4\/12), and skin and subcutaneous tissue disorder (4\/12) after\u2009&gt;\u2009360\u00a0days; no new safety signals were identified during the extended follow-up period.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>\n                      With a\u2009&gt;\u200924-month median follow-up, this analysis indicates that ENC\u2009+\u2009BIN provides sustained tumor responses in patients with\n                      <jats:italic>BRAF<\/jats:italic>\n                      V600-mutated thyroid cancer. The long-term safety profile is consistent with previous reports.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s10147-026-03129-5","type":"journal-article","created":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T14:02:43Z","timestamp":1785506563000},"page":"2223-2233","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Encorafenib plus binimetinib for BRAF V600-mutated thyroid cancer in Japan: final analysis"],"prefix":"10.1007","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5560-0706","authenticated-orcid":false,"given":"Iwao","family":"Sugitani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8021-6116","authenticated-orcid":false,"given":"Naomi","family":"Kiyota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1319-724X","authenticated-orcid":false,"given":"Hiroo","family":"Imai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5031-1953","authenticated-orcid":false,"given":"Shunji","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akihiro","family":"Nishiyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7105-4805","authenticated-orcid":false,"given":"Shingo","family":"Tamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2624-4305","authenticated-orcid":false,"given":"Yasushi","family":"Shimizu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9923-5309","authenticated-orcid":false,"given":"Shigenori","family":"Kadowaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6430-0307","authenticated-orcid":false,"given":"Ken-ichi","family":"Ito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshinori","family":"Hirashima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinji","family":"Ueno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-9644-9397","authenticated-orcid":false,"given":"Teruaki","family":"Katayama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9035-3106","authenticated-orcid":false,"given":"Makoto","family":"Tahara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,31]]},"reference":[{"issue":"3","key":"3129_CR1","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1016\/j.cell.2014.09.050","volume":"159","author":"N Agrawal","year":"2014","unstructured":"Agrawal N, Akbani R, Aksoy BA et al (2014) Integrated genomic characterization of papillary thyroid carcinoma. Cell 159(3):676\u2013690. https:\/\/doi.org\/10.1016\/j.cell.2014.09.050","journal-title":"Cell"},{"issue":"2","key":"3129_CR2","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1677\/erc.1.0978","volume":"12","author":"M Xing","year":"2005","unstructured":"Xing M (2005) BRAF mutation in thyroid cancer. Endocr Relat Cancer 12(2):245\u2013262. https:\/\/doi.org\/10.1677\/erc.1.0978","journal-title":"Endocr Relat Cancer"},{"issue":"10","key":"3129_CR3","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1038\/nrendo.2011.142","volume":"7","author":"YE Nikiforov","year":"2011","unstructured":"Nikiforov YE, Nikiforova MN (2011) Molecular genetics and diagnosis of thyroid cancer. Nat Rev Endocrinol 7(10):569\u2013580. https:\/\/doi.org\/10.1038\/nrendo.2011.142","journal-title":"Nat Rev Endocrinol"},{"issue":"7","key":"3129_CR4","doi-asserted-by":"publisher","first-page":"1764","DOI":"10.1002\/cncr.26500","volume":"118","author":"TH Kim","year":"2012","unstructured":"Kim TH, Park YJ, Lim JA et al (2012) The association of the BRAF(V600E) mutation with prognostic factors and poor clinical outcome in papillary thyroid cancer: a meta-analysis. Cancer 118(7):1764\u20131773. https:\/\/doi.org\/10.1002\/cncr.26500","journal-title":"Cancer"},{"issue":"8","key":"3129_CR5","doi-asserted-by":"publisher","first-page":"2104","DOI":"10.3390\/cancers12082104","volume":"12","author":"M Al-Jundi","year":"2020","unstructured":"Al-Jundi M, Thakur S, Gubbi S et al (2020) Novel targeted therapies for metastatic thyroid cancer\u2014a comprehensive review. Cancers (Basel) 12(8):2104. https:\/\/doi.org\/10.3390\/cancers12082104","journal-title":"Cancers (Basel)"},{"key":"3129_CR6","doi-asserted-by":"publisher","first-page":"806851","DOI":"10.3389\/fbioe.2022.806851","volume":"10","author":"Q Yi","year":"2022","unstructured":"Yi Q, Peng J, Xu Z et al (2022) Spectrum of BRAF aberrations and its potential clinical implications: insights from integrative pan-cancer analysis. Front Bioeng Biotechnol 10:806851. https:\/\/doi.org\/10.3389\/fbioe.2022.806851","journal-title":"Front Bioeng Biotechnol"},{"issue":"14","key":"3129_CR7","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.1001\/jama.2013.3190","volume":"309","author":"M Xing","year":"2013","unstructured":"Xing M, Alzahrani AS, Carson KA et al (2013) Association between BRAF V600E mutation and mortality in patients with papillary thyroid cancer. JAMA 309(14):1493\u20131501. https:\/\/doi.org\/10.1001\/jama.2013.3190","journal-title":"JAMA"},{"issue":"10","key":"3129_CR8","doi-asserted-by":"publisher","first-page":"3943","DOI":"10.1210\/jc.2008-0607","volume":"93","author":"R Elisei","year":"2008","unstructured":"Elisei R, Ugolini C, Viola D et al (2008) BRAF(V600E) mutation and outcome of patients with papillary thyroid carcinoma: a 15-year median follow-up study. J Clin Endocrinol Metab 93(10):3943\u20133949. https:\/\/doi.org\/10.1210\/jc.2008-0607","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"3129_CR9","doi-asserted-by":"publisher","first-page":"1878","DOI":"10.21037\/gs-20-430","volume":"9","author":"FA Rashid","year":"2020","unstructured":"Rashid FA, Munkhdelger J, Fukuoka J et al (2020) Prevalence of BRAF(V600E) mutation in Asian series of papillary thyroid carcinoma\u2014a contemporary systematic review. Gland Surg 9(5):1878\u20131900. https:\/\/doi.org\/10.21037\/gs-20-430","journal-title":"Gland Surg"},{"issue":"2","key":"3129_CR10","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1007\/s12022-017-9470-y","volume":"28","author":"N Oishi","year":"2017","unstructured":"Oishi N, Kondo T, Nakazawa T et al (2017) Frequent BRAF (V600E) and absence of TERT promoter mutations characterize sporadic pediatric papillary thyroid carcinomas in Japan. Endocr Pathol 28(2):103\u2013111. https:\/\/doi.org\/10.1007\/s12022-017-9470-y","journal-title":"Endocr Pathol"},{"issue":"2","key":"3129_CR11","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1007\/s12020-024-03738-y","volume":"85","author":"H Yamazaki","year":"2024","unstructured":"Yamazaki H, Kunisaki C, Sugimori M et al (2024) Genetic landscape of 482 thyroid carcinomas: analysis with the national datacenter for cancer genomic medicine in Japan. Endocr 85(2):766\u2013776. https:\/\/doi.org\/10.1007\/s12020-024-03738-y","journal-title":"Endocr"},{"key":"3129_CR12","doi-asserted-by":"publisher","first-page":"102","DOI":"10.3389\/fendo.2020.00102","volume":"11","author":"A Prete","year":"2020","unstructured":"Prete A, Borges de Souza P, Censi S et al (2020) Update on fundamental mechanisms of thyroid cancer. Front Endocrinol (Lausanne) 11:102. https:\/\/doi.org\/10.3389\/fendo.2020.00102","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"10","key":"3129_CR13","doi-asserted-by":"publisher","first-page":"1505","DOI":"10.1089\/thy.2020.0086","volume":"30","author":"B Xu","year":"2020","unstructured":"Xu B, Fuchs T, Dogan S et al (2020) Dissecting anaplastic thyroid carcinoma: a comprehensive clinical, histologic, immunophenotypic, and molecular study of 360 cases. Thyroid 30(10):1505\u20131517. https:\/\/doi.org\/10.1089\/thy.2020.0086","journal-title":"Thyroid"},{"issue":"11","key":"3129_CR14","doi-asserted-by":"publisher","first-page":"2784","DOI":"10.1210\/clinem\/dgae271","volume":"109","author":"S Toda","year":"2024","unstructured":"Toda S, Hiroshima Y, Iwasaki H et al (2024) Genomic landscape and clinical features of advanced thyroid carcinoma: a national database study in Japan. J Clin Endocrinol Metab 109(11):2784\u20132792. https:\/\/doi.org\/10.1210\/clinem\/dgae271","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"3129_CR15","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1038\/s41591-023-02321-8","volume":"29","author":"V Subbiah","year":"2023","unstructured":"Subbiah V, Kreitman RJ, Wainberg ZA et al (2023) Dabrafenib plus trametinib in BRAFV600E-mutated rare cancers: the phase 2 ROAR trial. Nat Med 29(5):1103\u20131112. https:\/\/doi.org\/10.1038\/s41591-023-02321-8","journal-title":"Nat Med"},{"key":"3129_CR16","doi-asserted-by":"publisher","first-page":"102447","DOI":"10.1016\/j.eclinm.2024.102447","volume":"69","author":"T Shimoi","year":"2024","unstructured":"Shimoi T, Sunami K, Tahara M et al (2024) Dabrafenib and trametinib administration in patients with BRAF V600E\/R or non-V600 BRAF mutated advanced solid tumours (BELIEVE, NCCH1901): a multicentre, open-label, and single-arm phase II trial. Eclinicalmed 69:102447. https:\/\/doi.org\/10.1016\/j.eclinm.2024.102447","journal-title":"Eclinicalmed"},{"issue":"4","key":"3129_CR17","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1089\/thy.2023.0547","volume":"34","author":"M Tahara","year":"2024","unstructured":"Tahara M, Kiyota N, Imai H et al (2024) A phase 2 study of encorafenib in combination with binimetinib in patients with metastatic BRAF-mutated thyroid cancer in Japan. Thyroid 34(4):467\u2013476. https:\/\/doi.org\/10.1089\/thy.2023.0547","journal-title":"Thyroid"},{"issue":"18","key":"3129_CR18","doi-asserted-by":"publisher","first-page":"5339","DOI":"10.1158\/1078-0432.CCR-16-2923","volume":"23","author":"JP Delord","year":"2017","unstructured":"Delord JP, Robert C, Nyakas M et al (2017) Phase I dose-escalation and -expansion study of the BRAF inhibitor encorafenib (LGX818) in metastatic BRAF-mutant melanoma. Clin Cancer Res 23(18):5339\u20135348. https:\/\/doi.org\/10.1158\/1078-0432.CCR-16-2923","journal-title":"Clin Cancer Res"},{"issue":"2","key":"3129_CR19","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1097\/CCO.0000000000000426","volume":"30","author":"P Koelblinger","year":"2018","unstructured":"Koelblinger P, Thuerigen O, Dummer R (2018) Development of encorafenib for BRAF-mutated advanced melanoma. Curr Opin Oncol 30(2):125\u2013133. https:\/\/doi.org\/10.1097\/CCO.0000000000000426","journal-title":"Curr Opin Oncol"},{"issue":"10","key":"3129_CR20","doi-asserted-by":"publisher","first-page":"1184","DOI":"10.1089\/thy.2022.0115","volume":"32","author":"NL Busaidy","year":"2022","unstructured":"Busaidy NL, Konda B, Wei L et al (2022) Dabrafenib versus dabrafenib + trametinib in BRAF-mutated radioactive iodine refractory differentiated thyroid cancer: results of a randomized, phase 2, open-label multicenter trial. Thyroid 32(10):1184\u20131192. https:\/\/doi.org\/10.1089\/thy.2022.0115","journal-title":"Thyroid"},{"key":"3129_CR21","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1016\/j.ejca.2016.03.082","volume":"62","author":"LH Schwartz","year":"2016","unstructured":"Schwartz LH, Seymour L, Liti\u00e8re S et al (2016) RECIST 1.1 - standardisation and disease-specific adaptations: perspectives from the RECIST Working Group. Eur J Cancer 62:138\u2013145. https:\/\/doi.org\/10.1016\/j.ejca.2016.03.082","journal-title":"Eur J Cancer"},{"issue":"5","key":"3129_CR22","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1016\/S1470-2045(18)30142-6","volume":"19","author":"R Dummer","year":"2018","unstructured":"Dummer R, Ascierto PA, Gogas HJ et al (2018) Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol 19(5):603\u2013615. https:\/\/doi.org\/10.1016\/S1470-2045(18)30142-6","journal-title":"Lancet Oncol"},{"issue":"36","key":"3129_CR23","doi-asserted-by":"publisher","first-page":"4178","DOI":"10.1200\/JCO.21.02659","volume":"40","author":"R Dummer","year":"2022","unstructured":"Dummer R, Flaherty KT, Robert C et al (2022) COLUMBUS 5-year update: a randomized, open-label, phase III trial of encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF V600-mutant melanoma. J Clin Oncol 40(36):4178\u20134188. https:\/\/doi.org\/10.1200\/JCO.21.02659","journal-title":"J Clin Oncol"},{"key":"3129_CR24","doi-asserted-by":"publisher","first-page":"114073","DOI":"10.1016\/j.ejca.2024.114073","volume":"204","author":"D Schadendorf","year":"2024","unstructured":"Schadendorf D, Dummer R, Flaherty KT et al (2024) COLUMBUS 7-year update: a randomized, open-label, phase III trial of encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF V600E\/K-mutant melanoma. Eur J Cancer 204:114073. https:\/\/doi.org\/10.1016\/j.ejca.2024.114073","journal-title":"Eur J Cancer"},{"issue":"4","key":"3129_CR25","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1007\/s10147-025-02693-6","volume":"30","author":"N Yamazaki","year":"2025","unstructured":"Yamazaki N, Sakata H, Iida O et al (2025) Post-marketing surveillance of encorafenib in combination with binimetinib in Japanese patients with BRAF-mutant melanoma. Int J Clin Oncol 30(4):814\u2013823. https:\/\/doi.org\/10.1007\/s10147-025-02693-6","journal-title":"Int J Clin Oncol"},{"issue":"12","key":"3129_CR26","doi-asserted-by":"publisher","first-page":"1748","DOI":"10.1016\/j.ophtha.2021.05.008","volume":"128","author":"C Mettler","year":"2021","unstructured":"Mettler C, Monnet D, Kramkimel N et al (2021) Ocular safety profile of BRAF and MEK inhibitors: data from the World Health Organization pharmacovigilance database. Ophthalmology 128(12):1748\u20131755. https:\/\/doi.org\/10.1016\/j.ophtha.2021.05.008","journal-title":"Ophthalmology"},{"issue":"3","key":"3129_CR27","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1007\/s11912-022-01205-3","volume":"24","author":"PY Courand","year":"2022","unstructured":"Courand PY, Berger M, Bouali A et al (2022) Cardiac effects of BRAF and MEK inhibitors: mechanisms and clinical management. Curr Oncol Rep 24(3):265\u2013271. https:\/\/doi.org\/10.1007\/s11912-022-01205-3","journal-title":"Curr Oncol Rep"},{"issue":"9","key":"3129_CR28","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1016\/S1470-2045(16)30122-X","volume":"17","author":"PA Ascierto","year":"2016","unstructured":"Ascierto PA, McArthur GA, Dr\u00e9no B et al (2016) Cobimetinib combined with vemurafenib in advanced BRAF(V600)-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial. Lancet Oncol 17(9):1248\u20131260. https:\/\/doi.org\/10.1016\/S1470-2045(16)30122-X","journal-title":"Lancet Oncol"}],"container-title":["International Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-026-03129-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10147-026-03129-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-026-03129-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T16:49:48Z","timestamp":1790354988000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10147-026-03129-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,31]]},"references-count":28,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["3129"],"URL":"https:\/\/doi.org\/10.1007\/s10147-026-03129-5","relation":{},"ISSN":["1341-9625","1437-7772"],"issn-type":[{"value":"1341-9625","type":"print"},{"value":"1437-7772","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,31]]},"assertion":[{"value":"12 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"I.S. received institutional grants from Bayer and Eisai; honoraria and travel support from Eli Lilly, Eisai, Ono Pharmaceutical (ONO), and Novartis; and served advisory boards for Takeda and Eli Lilly. N.K. received a research grant from ONO, Abbvie, Boehringer Ingelheim, GlaxoSmithKline (GSK) and Kyowa Kirin; and honoraria from Bayer, Eisai, ONO, Eli Lilly, Novartis, Merck Biopharma, and Merck Sharp & Dohme (MSD) and Daiichi Sankyo. S.Tak. received grants and honoraria from Daiichi-Sankyo, Novartis, Chugai Pharma, Bristol-Myers Squibb (BMS), Eisai, MSD, AstraZeneca, and Taiho Pharmaceutical; and honorarium from ONO. S.Tam. received honoraria for a speaker from Bayer Pharma Japan, Chugai, Eli Lilly Japan, Daiichi-Sankyo, ONO, and MSD K.K. Y.S. received a research grant from MSD; and honoraria from ONO, Eisai, Eli Lilly, MSD, Bristol-Myers Squibb, and Merck Biopharma. S.K. received grants from ONO, Taiho Pharmaceutical, MSD, Nobelpharma, Janssen Pharmaceutical K.K., BMS, Eli Lilly, Chugai, Daiichi-Sankyo, AstraZeneca, Abbvie, Kyowa Kirin, Astellas, Novartis, and Bayer; and honoraria from ONO, Taiho Pharmaceutical, MSD, Daiichi-Sankyo, Merck KGaA, BMS, Eli Lilly, Chugai, Bayer, Eisai, Novartis, and Astellas. K.I. received lecture payment from ONO, Eli Lilly, and Novartis. Y.H., S.U., and T.K. are employed by ONO. M.T. received grants from ONO, Bayer; consulting fees from Boehringer Ingelheim, Janssen Pharmaceutical, Genmab, AbbVie, and Astellas; and honorarial from ONO, MSD, Bayer, Rakuten Medical, BMS, Merck Biopharma, Eisai, Eli Lilly and Novartis; and served on advisory boards for MSD, Bayer, BMS, Eisai, AstraZeneca, Merus, Merck Biopharma, Pfizer, Eli Lilly, Boehringer Ingelheim, GSK, and Johnson&Johnson. H.I. and A.N. declare no conflicts.","order":1,"name":"Ethics","label":"Conflicts of interest","group":{"name":"EthicsHeading","label":"Declarations"}}]}}